News

Labiotech.eu6d
Myasthenia gravis treatments: what’s on the horizon?
Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.
Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight
Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...
MedPage Today1mon
FDA Approves Nipocalimab for Adult and Pediatric Myasthenia Gravis
The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle ...
The Victoria Advocate1mon
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia ...
He has not been paid for any media work. Nipocalimab is an investigational monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G ...
Finanznachrichten2mon
Johnson & Johnson: New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia ...
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMG a score in ...
Nasdaq2mon
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren ...
Seeking Alpha2mon
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's ...
March 18, 2025 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD ...